Published in Breast Cancer Res on March 27, 2008
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A (2010) 2.79
PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Cell Cycle (2009) 1.54
Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol (2010) 1.27
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res Treat (2012) 1.26
A fuzzy gene expression-based computational approach improves breast cancer prognostication. Genome Biol (2010) 1.16
Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases. Breast Cancer Res (2011) 0.93
PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients. Clinics (Sao Paulo) (2012) 0.91
Prognostic role of PIK3CA mutations and their association with hormone receptor expression in breast cancer: a meta-analysis. Sci Rep (2014) 0.86
PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy. Virchows Arch (2012) 0.83
Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 genes and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer. J Cancer Res Clin Oncol (2010) 0.83
Prognostic and predictive value of Phospho-p44/42 and pAKT in HER2-positive locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy. World J Surg Oncol (2013) 0.81
PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy. Virchows Arch (2014) 0.79
Proteins Involved in HER2 Signalling Pathway, Their Relations and Influence on Metastasis-Free Survival in HER2-Positive Breast Cancer Patients Treated with Trastuzumab in Adjuvant Setting. J Cancer (2017) 0.75
Molecular portraits of human breast tumours. Nature (2000) 94.14
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res (2005) 8.98
The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther (2004) 7.82
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol (2005) 7.43
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol (2006) 7.24
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol (2007) 7.00
Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res (2004) 6.65
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol (2008) 6.31
Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate. Nature (1988) 5.88
Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A (2006) 4.84
Purification and characterization of phosphoinositide 3-kinase from rat liver. J Biol Chem (1990) 4.75
Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res (2005) 4.14
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene (2005) 4.07
Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol Cancer Res (2007) 3.21
Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res (2007) 3.12
HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene (2003) 2.84
Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat (2003) 2.26
Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res (2005) 2.20
Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol (2007) 2.19
Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem Sci (2007) 1.90
Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res (2000) 1.46
Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells. Br J Cancer (2003) 1.25
Intranuclear 3'-phosphoinositide metabolism and Akt signaling: new mechanisms for tumorigenesis and protection against apoptosis? Cell Signal (2006) 1.22
Point mutations of protein kinases and individualised cancer therapy. Expert Opin Pharmacother (2006) 0.94
Nuclear phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 3-kinase, Akt, and PTen: emerging key regulators of anti-apoptotic signaling and carcinogenesis. Eur J Histochem (2007) 0.86
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol (2006) 30.90
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
International network of cancer genome projects. Nature (2010) 20.35
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med (2011) 13.74
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 13.25
Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med (2011) 12.52
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol (2008) 11.73
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol (2008) 11.03
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 10.89
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol (2009) 10.18
Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res (2005) 9.70
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature (2012) 9.39
Gene-expression signatures in breast cancer. N Engl J Med (2009) 9.23
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature (2012) 8.77
Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol (2009) 8.55
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA (2010) 8.21
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol (2013) 7.97
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Hum Mutat (2009) 7.68
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature (2002) 7.46
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol (2005) 7.43
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet (2012) 7.31
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol (2006) 7.24
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol (2007) 7.00
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 6.76
Cyclin E and survival in patients with breast cancer. N Engl J Med (2002) 6.44
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med (2011) 6.21
Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol (2005) 6.18
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist (2009) 6.00
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68
Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol (2009) 5.64
Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res (2007) 5.54
Colorectal cancer: mutations in a signalling pathway. Nature (2005) 5.42
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol (2008) 5.19
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol (2006) 4.91
Breast carcinoma in men: a population-based study. Cancer (2004) 4.88
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res (2009) 4.82
Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol (2014) 4.76
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science (2004) 4.67
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA (2011) 4.63
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med (2015) 4.53
IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell (2007) 4.48
Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst (2009) 4.42
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol (2007) 4.23
Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell (2004) 4.17
A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer. N Engl J Med (2015) 4.07
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol (2009) 4.05
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol (2005) 4.03
Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol (2007) 3.93
Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med (2012) 3.86
Trastuzumab in the treatment of breast cancer. N Engl J Med (2005) 3.86
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov (2011) 3.86
Bone imaging in metastatic breast cancer. J Clin Oncol (2004) 3.85
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol (2005) 3.83
Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet (2011) 3.60
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol (2006) 3.58
Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res (2007) 3.53
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol (2006) 3.52
Mammography before diagnosis among women age 80 years and older with breast cancer. J Clin Oncol (2008) 3.49
Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol (2007) 3.46
Male breast cancer. Lancet (2006) 3.41
Breast cancer in men. Ann Intern Med (2002) 3.39
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA (2013) 3.38
Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med (2012) 3.38